Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Core and Main Inc (CNM) vs TG Therapeutics Inc (TGTX) Price & Performance

Core and Main IncTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Core and Main Inc vs TG Therapeutics Inc — how do they compare? Core and Main Inc trades at $45.86 (market cap $8.62B), while TG Therapeutics Inc trades at $48.58 (market cap $7.58B). The key difference: Core and Main Inc and TG Therapeutics Inc are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Core and Main Inc nearer its low. Which is the better fit depends on your goals.

CNMTGTX
Market Cap
$8.62B$7.58B
Sector
TechnologyHealth
52-Week High
$66.98$59.06
52-Week Low
$42.37$26.94
Enterprise Value
$10.92B$7.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Core and Main Inc

Core & Main (CNM) trades at $46.06, down 0.52% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.57 exceeding expectations. Financials show solid profitability with a 5.87% net income margin and 23.73% ROE, though debt levels remain elevated. Recent news includes institutional position adjustments and a $750 million senior notes offering priced in June 2026.

Outlook is cautiously optimistic with analyst consensus favoring Buy ratings (57%). Key opportunities include margin expansion and municipal strength, while risks involve high debt, competitive pressures, and reliance on infrastructure spending. The stock's valuation at a P/E of 19.76 appears reasonable given growth prospects, but investors should monitor execution against FY26 revenue guidance of $7.8–7.9 billion.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Core and Main Inc

Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.

Read more on CNM

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX